MARKET OVERVIEW

Prediction markets currently price retatrutide's chance of receiving FDA approval by December 31, 2026 at 23.5%, implying roughly a one-in-four likelihood of regulatory success within the next two years. The drug, being developed by Eli Lilly to treat obesity, type 2 diabetes, fatty liver disease, and knee osteoarthritis, must complete phase 3 trials and undergo FDA review to qualify for approval under the market's broad definition, which includes standard, accelerated, and conditional approvals across all indicated uses.

WHY IT MATTERS

Retatrutide represents a significant potential addition to Eli Lilly's metabolic disease portfolio, following the commercial success of tirzepatide (Mounjaro/Zepbound), a dual GLP-1/GIP agonist. A successful approval would establish a new class of triple agonists (adding an FGF21 component to the GLP-1/GIP mechanism) with potentially differentiated efficacy in weight loss and metabolic outcomes. The current odds suggest market participants view regulatory approval within the specified timeframe as moderately unlikely, though not improbable—a reflection of standard drug development timelines rather than fundamental concerns about the compound's safety or efficacy profile.

KEY FACTORS DRIVING PROBABILITY

Several factors constrain the approval timeline. Retatrutide is currently in late-stage clinical development across multiple indications, with trials still enrolling or generating efficacy and safety data. FDA review periods typically span 10-12 months for standard review or 6 months for priority review following application submission. The market's 23.5% probability effectively requires retatrutide's NDA or BLA to be submitted by mid-2025 and granted approval without significant additional data requests—a compressed timeline for a multi-indication candidate. The breadth of retatrutide's development program (five distinct clinical applications) may also extend trial completion and regulatory pathways. Conversely, Eli Lilly's established relationship with the FDA, demonstrated manufacturing infrastructure, and positive early efficacy signals in obesity trials could accelerate review if priority review is granted.

OUTLOOK

Key milestones that could shift market odds include phase 3 topline data releases, FDA meeting outcomes on trial design adequacy, and formal NDA/BLA submission announcements. An accelerated approval for the obesity indication—the company's highest-priority use case given commercial demand—would substantially increase approval probability within the two-year window. Conversely, delays in patient enrollment, safety signals, or FDA requests for additional studies would lower odds. Market participants should monitor Eli Lilly's earnings calls and regulatory filing timelines for updates on trial status and anticipated submission dates.